dc.contributor.author | Rayego-Mateos, Sandra | |
dc.contributor.author | Morgado-Pascual, José Luis | |
dc.contributor.author | Opazo-Ríos, Lucas | |
dc.contributor.author | Guerrero-Hue, Melania | |
dc.contributor.author | García-Caballero, Cristina | |
dc.contributor.author | Vázquez-Carballo, Cristina | |
dc.contributor.author | Mas, Sebastián | |
dc.contributor.author | Sanz, Ana Belén | |
dc.contributor.author | Herencia, Carmen | |
dc.contributor.author | Mezzano, Sergio | |
dc.contributor.author | Gómez Guerrero, Carmen | |
dc.contributor.author | Moreno, Juan Antonio | |
dc.contributor.author | Egido, Jesús | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.contributor.other | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) | es_ES |
dc.date.accessioned | 2021-03-17T07:38:24Z | |
dc.date.available | 2021-03-17T07:38:24Z | |
dc.date.issued | 2020-06-01 | |
dc.identifier.citation | International Journal of Molecular Sciences 21.11 (2020): 3798 | en_US |
dc.identifier.issn | 1661-6596 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/694177 | |
dc.description.abstract | Diabetic nephropathy (DN) is associated with an increased morbidity and mortality, resulting in elevated cost for public health systems. DN is the main cause of chronic kidney disease (CKD) and its incidence increases the number of patients that develop the end-stage renal disease (ESRD). There are growing epidemiological and preclinical evidence about the close relationship between inflammatory response and the occurrence and progression of DN. Several antiinflammatory strategies targeting specific inflammatory mediators (cell adhesion molecules, chemokines and cytokines) and intracellular signaling pathways have shown beneficial effects in experimental models of DN, decreasing proteinuria and renal lesions. A number of inflammatory molecules have been shown useful to identify diabetic patients at high risk of developing renal complications. In this review, we focus on the key role of inflammation in the genesis and progression of DN, with a special interest in effector molecules and activated intracellular pathways leading to renal damage, as well as a comprehensive update of new therapeutic strategies targeting inflammation to prevent and/or retard renal injury. | en_US |
dc.description.sponsorship | The authors work has been supported by grants from Instituto de Salud Carlos III (ISCIII, FIS-FEDER PI17/00130, PI17/01495, PI19/00588, ERA-PerMed-JTC2018-PERSTIGAN AC18/00071), Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM) and Cardiovascular (CIBERCV), Fondecyt
Project (No. 1160465), Spanish Ministry of Science and Innovation (RTI2018-098788-B-100, DTS17/00203, DTS19/00093, RYC-2017-22369), and Spanish Societies of Cardiology (SEC), Nephrology (SEN) and Atherosclerosis (SEA). The “PFIS” and “Sara Borrell” training program of the ISCIII supported the salary of MGH (FI18/00310),
SR-M (CD19/00021) and CH-B (CP16/00017). Córdoba University supported the salary of C.G.C. | en_US |
dc.format.extent | 43 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en_US |
dc.publisher | MDPI, Basel, SMwitzerland | en_US |
dc.relation.ispartof | International Journal of Molecular Sciences | en_US |
dc.rights | © 2020 The Authors | en_US |
dc.subject.other | And therapy | en_US |
dc.subject.other | Chronic kidney disease | en_US |
dc.subject.other | Diabetic nephropathy | en_US |
dc.subject.other | Drugs | en_US |
dc.subject.other | Inflammation | en_US |
dc.subject.other | Type 2 diabetes | en_US |
dc.title | Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://doi.org/10.3390/ijms21113798 | es_ES |
dc.identifier.doi | 10.3390/ijms21113798 | es_ES |
dc.identifier.publicationfirstpage | 3798-1 | es_ES |
dc.identifier.publicationissue | 11 | es_ES |
dc.identifier.publicationlastpage | 3798-43 | es_ES |
dc.identifier.publicationvolume | 21 | es_ES |
dc.relation.projectID | Gobierno de España. PI17/00130 | es_ES |
dc.relation.projectID | Gobierno de España. PI17/01495 | es_ES |
dc.relation.projectID | Gobierno de España. PI19/00588 | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/779282/EU//ERA-PerMed | es_ES |
dc.relation.projectID | Gobierno de España. RTI2018-098788-B-100 | es_ES |
dc.relation.projectID | Gobierno de España. DTS17/00203 | es_ES |
dc.relation.projectID | Gobierno de España. DTS19/00093 | es_ES |
dc.relation.projectID | Gobierno de España. RYC-2017-22369 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | Reconocimiento | es_ES |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Vázquez Carballo, Cristina (281317) | |
dc.authorUAM | Gómez Guerrero, Carmen (261179) | |
dc.authorUAM | Egido De Los Ríos, Jesús (259718) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD) | |